{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:08:56Z","timestamp":1778872136594,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1245\/s10434-025-18995-y","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T17:19:44Z","timestamp":1767806384000},"page":"5441-5457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["NUP62 Elevates USP10 Expression and Promotes Tamoxifen Resistance of Breast Cancer by Deubiquitinating ER\u03b1"],"prefix":"10.1245","volume":"33","author":[{"given":"Zhihuai","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Likai","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xihu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"2","key":"18995_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","volume":"83","author":"C Katsura","year":"2022","unstructured":"Katsura C, Ogunmwonyi I, Kankam HK, et al. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond). 2022;83(2):1\u20137.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"3","key":"18995_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"18995_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390.","journal-title":"Lancet Oncol"},{"issue":"12","key":"18995_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41571-022-00687-1","volume":"19","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Gligorov J, Piccart M. Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nat Rev Clin Oncol. 2022;19(12):763\u201374.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"18995_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","volume":"99","author":"O Saatci","year":"2021","unstructured":"Saatci O, Huynh-Dam KT, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med (Berl). 2021;99(12):1691\u2013710.","journal-title":"J Mol Med (Berl)"},{"key":"18995_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115552","volume":"212","author":"B Blakely","year":"2023","unstructured":"Blakely B, Shin S, Jin K. Overview of the therapeutic strategies for ER positive breast cancer. Biochem Pharmacol. 2023;212:115552.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"18995_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1677\/erc.1.00776","volume":"11","author":"A Ring","year":"2004","unstructured":"Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643\u201358.","journal-title":"Endocr Relat Cancer"},{"key":"18995_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.599586","volume":"12","author":"EB Belachew","year":"2021","unstructured":"Belachew EB, Sewasew DT. Molecular mechanisms of endocrine resistance in estrogen-positive breast cancer. Front Endocrinol (Lausanne). 2021;12:599586.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"18995_CR9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/cbin.10633","volume":"40","author":"Z Wu","year":"2016","unstructured":"Wu Z, Jin Z, Zhang X, et al. Nup62, associated with spindle microtubule rather than spindle matrix, is involved in chromosome alignment and spindle assembly during mitosis. Cell Biol Int. 2016;40(9):968\u201375.","journal-title":"Cell Biol Int"},{"issue":"24","key":"18995_CR10","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.4161\/cc.26671","volume":"12","author":"C Hashizume","year":"2013","unstructured":"Hashizume C, Moyori A, Kobayashi A, et al. Nucleoporin Nup62 maintains centrosome homeostasis. Cell Cycle. 2013;12(24):3804\u201316.","journal-title":"Cell Cycle"},{"issue":"3","key":"18995_CR11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.cell.2011.09.034","volume":"147","author":"SR Solmaz","year":"2011","unstructured":"Solmaz SR, Chauhan R, Blobel G, et al. Molecular architecture of the transport channel of the nuclear pore complex. Cell. 2011;147(3):590\u2013602.","journal-title":"Cell"},{"issue":"1","key":"18995_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1083\/jcb.114.1.169","volume":"114","author":"DR Finlay","year":"1991","unstructured":"Finlay DR, Meier E, Bradley P, et al. A complex of nuclear pore proteins required for pore function. J Cell Biol. 1991;114(1):169\u201383.","journal-title":"J Cell Biol"},{"issue":"1","key":"18995_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41368-025-00362-y","volume":"17","author":"X Wang","year":"2025","unstructured":"Wang X, Wang L, Zhou L, et al. NUP62 alleviates senescence and promotes the stemness of human dental pulp stem cells via NSD2-dependent epigenetic reprogramming. Int J Oral Sci. 2025;17(1):34.","journal-title":"Int J Oral Sci"},{"key":"18995_CR14","doi-asserted-by":"publisher","first-page":"1559396","DOI":"10.3389\/fimmu.2025.1559396","volume":"16","author":"L Chen","year":"2025","unstructured":"Chen L, He Y, Duan M, et al. Exploring NUP62\u2019s role in cancer progression, tumor immunity, and treatment response: insights from multi-omics analysis. Front Immunol. 2025;16:1559396.","journal-title":"Front Immunol"},{"key":"18995_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2020.105843","volume":"128","author":"ML Chien","year":"2020","unstructured":"Chien ML, Lai JH, Lin TF, et al. NUP62 is required for the maintenance of the spindle assembly checkpoint and chromosomal stability. Int J Biochem Cell Biol. 2020;128:105843.","journal-title":"Int J Biochem Cell Biol"},{"key":"18995_CR16","doi-asserted-by":"crossref","unstructured":"Akbar H, Cao J, Wang D et al. Acetylation of Nup62 by TIP60 ensures accurate chromosome segregation in mitosis. J Mol Cell Biol 2022; 14 (8).","DOI":"10.1093\/jmcb\/mjac056"},{"key":"18995_CR17","doi-asserted-by":"publisher","first-page":"1095046","DOI":"10.3389\/fonc.2023.1095046","volume":"13","author":"U Singh","year":"2023","unstructured":"Singh U, Bindra D, Samaiya A, et al. Overexpressed Nup88 stabilized through interaction with Nup62 promotes NF-\u03baB dependent pathways in cancer. Front Oncol. 2023;13:1095046.","journal-title":"Front Oncol"},{"issue":"2","key":"18995_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1615\/JEnvironPatholToxicolOncol.2021037136","volume":"40","author":"H Wang","year":"2021","unstructured":"Wang H, Lin Y, Jin J, et al. Nuclear pore complex 62 promotes metastasis of gastric cancer by regulating Wnt\/\u03b2-catenin and TGF-\u03b2 signaling pathways. J Environ Pathol Toxicol Oncol. 2021;40(2):81\u20137.","journal-title":"J Environ Pathol Toxicol Oncol"},{"issue":"1","key":"18995_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15252\/embr.201745497","volume":"19","author":"J Borlido","year":"2018","unstructured":"Borlido J, D\u2019Angelo MA. Nup62-mediated nuclear import of p63 in squamous cell carcinoma. EMBO Rep. 2018;19(1):3\u20134.","journal-title":"EMBO Rep"},{"key":"18995_CR20","doi-asserted-by":"crossref","unstructured":"Ferrari P, Schiavone ML, Scatena C et al. Molecular mechanisms and therapeutic strategies to overcome resistance to endocrine therapy and CDK4\/6 inhibitors in advanced ER+\/HER2- breast cancer. Int J Mol Sci 2025;26(7).","DOI":"10.3390\/ijms26073438"},{"issue":"4","key":"18995_CR21","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/cas.14813","volume":"112","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang J, Li J, et al. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4\/6 inhibitors in breast cancer. Cancer Sci. 2021;112(4):1603\u201313.","journal-title":"Cancer Sci"},{"key":"18995_CR22","doi-asserted-by":"crossref","unstructured":"Nabieva N, Fasching PA. CDK4\/6 Inhibitors-overcoming endocrine resistance is the standard in patients with hormone receptor-positive breast cancer. Cancers (Basel) 2023;15(6).","DOI":"10.3390\/cancers15061763"},{"issue":"1","key":"18995_CR23","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41598-023-29425-y","volume":"13","author":"MJ Rodriguez","year":"2023","unstructured":"Rodriguez MJ, Perrone MC, Riggio M, et al. Targeting mTOR to overcome resistance to hormone and CDK4\/6 inhibitors in ER-positive breast cancer models. Sci Rep. 2023;13(1):2710.","journal-title":"Sci Rep"},{"key":"18995_CR24","volume":"136","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zhang Y, Shen Y, et al. Liquidambaric acid inhibits cholangiocarcinoma progression by disrupting the STAMBPL1\/NRF2 positive feedback loop. Phytomed Int J Phytother Phytopharmacol. 2025;136:156303.","journal-title":"Phytomed Int J Phytother Phytopharmacol"},{"key":"18995_CR25","doi-asserted-by":"crossref","unstructured":"Li H, Liu Y, Cai Z et al. ARL3 enhances ER\u03b1 stability via USP10 deubiquitination to promote endocrine resistance and drive mitochondrial metabolic reprogramming in HR+ breast cancer. Adv Sci (Weinh) 2025:e09769.","DOI":"10.1002\/advs.202509769"},{"issue":"12","key":"18995_CR26","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439\u201345.","journal-title":"Nat Genet"},{"issue":"1","key":"18995_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","volume":"50","author":"M Akram","year":"2017","unstructured":"Akram M, Iqbal M, Daniyal M, et al. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33.","journal-title":"Biol Res"},{"key":"18995_CR28","doi-asserted-by":"crossref","unstructured":"Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer\u2014an overview and update. Mol Cell Endocrinol 2015;418 Pt 3 (0 3): 220\u2013234.","DOI":"10.1016\/j.mce.2015.09.035"},{"issue":"1","key":"18995_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11030-020-10133-y","volume":"25","author":"N Kumar","year":"2021","unstructured":"Kumar N, Gulati HK, Sharma A, et al. Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer. Mol Divers. 2021;25(1):603\u201324.","journal-title":"Mol Divers"},{"issue":"Pt 1","key":"18995_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.semcancer.2017.08.010","volume":"52","author":"A Nicolini","year":"2018","unstructured":"Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52(Pt 1):56\u201373.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"18995_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03267-x","volume":"480","author":"S Najjar","year":"2022","unstructured":"Najjar S, Allison KH. Updates on breast biomarkers. Virchows Arch. 2022;480(1):163\u201376.","journal-title":"Virchows Arch"},{"issue":"3","key":"18995_CR32","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/pros.23121","volume":"76","author":"LG Karacosta","year":"2016","unstructured":"Karacosta LG, Kuroski LA, Hofmann WA, et al. Nucleoporin 62 and Ca(2+)\/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells. Prostate. 2016;76(3):294\u2013306.","journal-title":"Prostate"},{"issue":"1","key":"18995_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.15252\/embr.201744523","volume":"19","author":"M Hazawa","year":"2018","unstructured":"Hazawa M, Lin DC, Kobayashi A, et al. ROCK-dependent phosphorylation of NUP62 regulates p63 nuclear transport and squamous cell carcinoma proliferation. EMBO Rep. 2018;19(1):73\u201388.","journal-title":"EMBO Rep"},{"issue":"3","key":"18995_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212\u201326.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"18995_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","volume":"38","author":"C Cheng","year":"2018","unstructured":"Cheng C, Geng F, Cheng X, et al. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38(1):27.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"18995_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13046-020-01690-z","volume":"39","author":"Q Tang","year":"2020","unstructured":"Tang Q, Chen J, Di Z, et al. TM4SF1 promotes EMT and cancer stemness via the Wnt\/\u03b2-catenin\/SOX2 pathway in colorectal cancer. J Exp Clin Cancer Res. 2020;39(1):232.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"18995_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/cac2.12130","volume":"41","author":"S Li","year":"2021","unstructured":"Li S, Zhang J, Qian S, et al. S100A8 promotes epithelial-mesenchymal transition and metastasis under TGF-\u03b2\/USF2 axis in colorectal cancer. Cancer Commun (Lond). 2021;41(2):154\u201370.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"18995_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12943-017-0700-1","volume":"16","author":"S Yang","year":"2017","unstructured":"Yang S, Liu Y, Li MY, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt\/\u03b2-catenin signaling pathway and EMT in non-small cell lung cancer. Mol Cancer. 2017;16(1):124.","journal-title":"Mol Cancer"},{"issue":"13","key":"18995_CR39","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1080\/15384101.2022.2052530","volume":"21","author":"C Dong","year":"2022","unstructured":"Dong C, Wu K, Gu S, et al. PTBP3 mediates TGF-\u03b2-induced EMT and metastasis of lung adenocarcinoma. Cell Cycle. 2022;21(13):1406\u201321.","journal-title":"Cell Cycle"},{"key":"18995_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217153","volume":"600","author":"L Huang","year":"2024","unstructured":"Huang L, Liu X, Chen Q, et al. TGF-\u03b2-induced lncRNA TBUR1 promotes EMT and metastasis in lung adenocarcinoma via hnRNPC-mediated GRB2 mRNA stabilization. Cancer Lett. 2024;600:217153.","journal-title":"Cancer Lett"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18995-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:27:13Z","timestamp":1778869633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18995-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["18995"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18995-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each author has declared the absence of conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The acquisition of human tumor specimens for this study received approval from the ethics committee of The Affiliated Changzhou Second People\u2019s Hospital of Nanjing Medical University (no.: 2023KY127-01), with informed consent obtained from all patients. Animal experiments were conducted in accordance with the regulations of the Ethics Committee of Jiangsu Kerbio Medical Technology Group Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}